Preclinical Development and Phase I Study of ZSYY001, a Polymeric Micellar Paclitaxel for Advanced Solid Tumor.

Cancer Med · 2025 · PMC12281596 · PMID 40693742

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Although pharmacokinetic parameters(C max , AUC 0‐t , and AUC 0‐∞ ) for both total and free paclitaxel showed an increasing trend with dose across the range of 175–390 mg/m 2 , the point estimates did not consistently fall within the confidence intervals.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.